Annual disease burden due to human papillomavirus 16 and 18 infections in Finland

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue SUPPL.108, 2009, Pages 2-32

  Syrjänen, Kari J ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

ANAL CANAL; ANTIBIOTIC PROPHYLAXIS; ANUS CANCER; BENIGN TUMOR; BLADDER CANCER; BRONCHUS CANCER; CARCINOGENESIS; COLON CANCER; CONDYLOMA ACUMINATUM; EPSTEIN BARR VIRUS; ESOPHAGUS CANCER; EYE CANCER; FINLAND; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INCIDENCE; INFECTION RATE; LARYNX CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; NASOPHARYNX CANCER; NOSE CANCER; OROPHARYNX CANCER; PARANASAL SINUS CANCER; PENIS CANCER; PREVALENCE; PUBLICATION; RECTUM CANCER; REVIEW; SCIENTIFIC LITERATURE; SKIN CANCER; SQUAMOUS CELL CARCINOMA; URETHRA CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; VACCINATION; VAGINA CANCER; VIRUS INFECTION; VULVA CANCER; ANUS CARCINOMA; ARTICLE; BASAL CELL CARCINOMA; BLADDER CARCINOMA; CANCER SCREENING; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVERTED PAPILLOMA; LARYNX CARCINOMA; LARYNX PAPILLOMATOSIS; LUNG SQUAMOUS CELL CARCINOMA; NASOPHARYNX CARCINOMA; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PARANASAL SINUS CARCINOMA; PATHOGENESIS; PENIS CARCINOMA; POLYMERASE CHAIN REACTION; PUNCH BIOPSY; SKIN CARCINOMA; URETHRA CARCINOMA; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VERRUCOUS CARCINOMA; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS LOAD; VULVA CARCINOMA; FEMALE; ISOLATION AND PURIFICATION; MALE; NEOPLASM; VIROLOGY;

FEMALE; FINLAND; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS;

EID: 73649148744     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903331985     Document Type: Review

References (154)

1. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol.64. Papillomaviruses. Lyon: IARC; 1995. pp. 1-409.
2. Syrjänen K, Syrjänen S. Papillomavirus infections in human pathology. Chichester: J. Wiley & Sons; 2000. pp. 1-615.
3. zur Hausen H. Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 2001;93:252-253
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2002; 2:342-350
5. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009;384: 260-265
6. Aubin F, Pretet JL, Mougin C. Papillomavirus humains. Biologie et pathologie tumorale. Paris: Editions TEC & DOC; 2003. pp. 1-759.
7. Campo S. Papillomavirus research: from natural history to vaccines and beyond. Norwich, UK: Caister Academic Press; 2006. pp. 1-424.
8. Coelho FR, Soares FA, Focchi J, Fregnani JH, de Andrade JM, Zeferino LC, et al. Câncer do colo do útero. Sao Paulo, Brazil: Tecmedd Editora; 2008. pp. 1-678.
9. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527
10. Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993; 67:6413-6423
11. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005;32S:S1-6.
12. Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001;93:1325-1330
13. Wang SS, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003;31:35-40.
14. Xi LF, Carter JJ, Galloway DA, Kuypers J, Hughes JP, Lee SK, et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002;11:343-351
15. de Villiers EM, Fauquet C, Broker TR, Bernhard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
16. Syrjänen S, Naud P, Derchain S, Sarian L, Roteli- Martins C, Longatto-Filho A, et al. Upregulation of plasminogen activator inhibitor-2 (PAI-2, Serpin-B2) is associated with high-risk human papillomavirus (HPV) and grade of cervical lesion at baseline but does not predict outcomes of HR-HPV infections or incident CIN. Am J Clin Pathol 2009; In press.
17. Syrjänen S, Naud P, Derchain S, Sarian L, Roteli- Martins C, Longatto-Filho A, et al. Upregulation of 14-3-3σ (Stratifin) is associated with high-grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS* Study. Am J Clin Pathol 2009; In press.
18. Syrjänen S. Human papillomaviruses in head and neck carcinomas. N Engl J Med 2007;356:1993-1995
19. Syrjänen K, Gissmann L, Koss LG. Papillomaviruses and human disease. Berlin: Springer; 1987. pp. 1-518.
20. Syrjänen, K. Overview of papillomavirus research. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 1-10.
21. Syrjänen S, Syrjänen K. The history of papillomavirus research. Cent Eur J Pub Health 2008;16:S7-13.
22. Villa LL, Costa R, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle (VLP) vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278
23. Harper DM, for the FUTURE I Study Group. Are we closer to the prevention of HPV-related diseases? Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, December 16-19, 2005.
24. Koutsky L for the FUTURE II Study Group. Current findings from prophylactic HPV Naccinetrials. Infectious Diseases Society of America Annual Meeting, San Francisco, CA, USA, October 6-9, 2005.
25. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008;26:6244-6257
26. Syrjänen K. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. Scand J Infect Dis Suppl 2009;107:3-32.
27. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. Vol.VII. IARC Scientific Publications. Lyon: IARC Press; 1997, p 142.
28. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. Version 2.0. IARC Cancer Base No. 5. Lyon: IARC Press; 2004.
29. http://www.cancerregistry.fi/tilastot/Visited date: September 5, 2009.
30. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S11-25.
31. Syrjänen, K. HPV and squamous cell tumours of the ocular surface epithelium. Chapter 19. In: Syrjänen K, Syrjänen S. Papillomavirus infections in human pathology. NewYork: J. Wiley & Sons; 2000. pp. 429-444
32. Sjo NC, von Buchwald, Cassonnet P, Norrild B, Prause JU, Vinding T, et al. Human papillomavirus in normal conjunctival tissue and in conjunctival papilloma: types and frequencies in a large series. Br J Ophthalmol 2007;91:1014-1015
33. Verma V, Shen D, Sieving PC, Chan CC. The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol 2008;53:312-331
34. Mäntyjärvi M, Syrjänen S, Kaipiainen S, Mäntyjärvi R, Kahlos T, Syrjänen K. Detection of human papillomavirus type 11 DNA in a conjunctival squamous cell papilloma by in situ hybridization with biotinylated probes. Acta Ophthalmol 1989;67:425-429
35. Syrjänen S. Human papillomavirus infections and oral tumors. Med Microbiol Immunol 2003;192:123-128
36. Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005;32(Suppl 1):59-66.
37. Syrjänen S, Syrjänen K. HPV infections of the oral mucosa. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 379-412.
38. Syrjänen K. HPV infections in the respiratory tract. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 355-378
39. Hyams VJ, Batsakis JG, Michaels L. Tumors of the upper respiratory tract and ear. Atlas of tumor pathology. Second series, fascicle 25. Washington DC: Armed Forces Institute of Pathology; 1986. pp. 34-82.
40. Sulica RL, Wenig BM, Debo RF, Sessions RB. Schneiderian papillomas of the pharynx. Ann Otol Rhinol Laryngol 1999;108:392-397
41. Low WK, Toh ST, Lim CM, Ramesh G. Schneiderian papilloma of the nasopharynx. Ear Nose Throat J 2002; 81:336-338
42. Syrjänen KJ, Pyrhönen S, Syrjänen SM. Evidence suggesting human papillomavirus (HPV) etiology for the squamous cell papilloma of the paranasal sinus. Arch Geschwulstforsch 1983;53:77-82.
43. Syrjänen KJ. HPV infections in benign and malignant sinonasal lesions. J Clin Pathol 2003;56:174-181
44. Klemi PJ, Joensuu H, Syrjänen S, Syrjänen K, Siivonen L, Virolainen E. Association of DNA aneuploidy with human papillomavirus induced malignant transformation of sinonasal transitional papillomas. Otolaryngol Head Neck Surg 1989;100:563-567
45. Syrjänen S. HPV-related squamous cell tumors of the airways and esophagus. Epidemiology and malignant potential. In: Gross G, von Krogh G, editors. Human papillomavirus infections in dermatovenereology. Boca Raton: CRC Press; 1997. pp. 181-199
46. Bielamowicz S, Calcaterra TC, Watson D. Inverting papilloma of the head and neck: the UCLA update. Otolaryngol Head Neck Surg 1993;109:71-76
47. Syrjänen K, Syrjänen S, Pyrhönen S. Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. J Otorhinolaryngol Relat Spec 1982; 44:323-334
48. Hobbs CG, Birchall MA. Human papillomavirus infection in the etiology of laryngeal carcinoma. Curr Opin Otolaryngol Head Neck Surg 2004;12:88-92.
49. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006;31:259-266
50. Silva AM, Vilanova-Costa CA, de Oliveira SF, da Silva CC, Curado MP, da Cruz AD. Human papillomavirus detection and genotyping in squamous cell carcinomas of the larynx. J Virol Methods 2009;157:231.
51. Lindeberg H, Syrjänen S, Kärjä J, Syrjänen K. Human papillomavirus (HPV) type 11 DNA in squamous cell carcinomas and pre-existing multiple laryngeal papillomas. Acta Otolaryngol 1989;107:141-149
52. Lindeberg H, Elbrönd O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984. Clin Otolaryngol 1991;15:125-131
53. Syrjänen KJ. Condylomatous changes in neoplastic bronchial epithelium. Report of a case. Respiration 1979;38: 299-304.
54. Syrjänen KJ. Epithelial lesions suggestive of a condylomatous origin found closely associated with invasive bronchial squamous cell carcinomas. Respiration 1980;40:150-160
55. Syrjänen KJ, Syrjänen SM. Human papillomavirus DNA in bronchial squamous cell carcinomas. Lancet 1987;1:168-169
56. Syrjänen K, Syrjänen S, Kellokoski J, Kärjä J, Mäntyjärvi R. Human papillomavirus (HPV) type 6 and 16 DNA sequences in bronchial squamous cell carcinomas demonstrated by in situ DNA hybridization. Lung 1989;167:33-42.
57. Bejui-Thivolet F, Chardonnet Y, Patricot LM. Human papillomavirus type 11 DNA in papillary squamous cell lung carcinoma. Virchows Arch A Pathol Anat Histopathol 1990; 417:457-461
58. DiLorenzo TP, Tamsen A, Abramson AL, Steinberg BM. Human papillomavirus type 6a DNA in the lung carcinoma of a patient with recurrent laryngeal papillomatosis is characterized by a partial duplication. J Gen Virol 1992;73:423-427
59. Yousem SA, Ohori NP, Sonmez-Alpan E. Occurrence of human papillomavirus DNA in primary lung neoplasms. Cancer 1992;69:693-697
60. al-Ghamdi AA, Sanders CM, Keefe M, Coggon D, Maitland NJ. Human papillomavirus DNA and TP53 mutations in lung cancers from butchers. Br J Cancer 1995;72:293-297
61. Nuorva K, Soini Y, Kamel D, Pöllänen R, Bloigu R, Vähäkangas K, et al. p53 protein accumulation and the presence of human papillomavirus DNA in bronchiolo-alveolar carcinoma correlate with poor prognosis. Int J Cancer 1995;64:424-429
62. Thomas P, De-Lamballerie X, Garbe L, Castelnau O, Kleisbauer JP. Detection of human papillomavirus DNA in primary lung carcinoma by nested polymerase chain reaction. Cell Mol Biol 1995;41:1093-1097
63. Thomas P, De-Lamballerie X, Garbe L, Castelnau O, Kleisbauer JP. Detection of human papillomavirus by polymerase chain reaction in primary lung carcinoma. Bull Cancer 1996;83:842-846
64. Noutsou A, Koffa M, Ergazaki M, Siafakas NM, Spandidos DA. Detection of human papilloma virus (HPV) and K-ras mutations in human lung carcinomas. Int J Oncol 1996; 8:1089-1093
65. Soini Y, Nuorva K, Kamel D, Pöllänen R, Vähäkangas K, Lehto VP, et al. Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma. Thorax 1996;51:887-893
66. Nakazato I, Hirayasu T, Kamada Y, Tsuhako K, Iwamasa T. Carcinoma of the lung in Okinawa, Japan: with special reference to squamous cell carcinoma and squamous metaplasia. Pathol Int 1997;47:659-672
67. Syrjänen K. HPV infections and lung cancer. J Clin Pathol 2002;55:885-891
68. Giuliani L, Favalli C, Syrjänen K, Ciotti M. Human papillomavirus (HPV) infections in lung cancer. Detection of E6 and E7 transcripts and review of the literature. Anticancer Res 2007;27:2697-2704
69. Roglic M, Jukic S, Damjanov I. Cytology of the solitary papilloma of the bronchus. Acta Cytol 1975;19:11-13
70. Rubel L, Reynolds RE. Cytologic description of squamous cell papilloma of the respiratory tract. Acta Cytol 1979; 23:227-231
71. Maxwell RJ, Gibbons JR, O'Hara MD. Solitary squamous papilloma of the bronchus. Thorax 1985;40:68-71.
72. Syrjänen K. HPV infections of the oesophagus. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 413-428
73. Syrjänen, K. HPV infections and oesophageal cancer. J Clin Pathol 2002;55:721-728
74. Syrjänen KJ, Pyrhönen S, Aukee S, Koskela E. Squamous cell papilloma of the oesophagus: a tumour probably caused by human papilloma virus (HPV). Diagn Histopathol 1982;5:291-296
75. Syrjänen KJ. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. Arch Geschwulstforsch 1982;52:283-292
76. Syrjänen K. HPV and oesophageal cancer. In: Campo S, editor. Papillomavirus research: from natural history to vaccines and beyond. Norwich, UK: Caister Academic Press; 2006. pp. 229-253
77. Syrjänen KJ. Human papillomavirus (HPV) involvement in esophageal carcinogenesis. In: Columbus F, editor. Viral cancer: etiology, pathogenesis and treatment. New York: Nova Science Publishing; 2009. In press.
78. Patterson EJ. Multiple papillomata of the esophagus: report of a case. Transact Am Bronchosc Soc 1928;5:1169-1172
79. Adler RH, Carberry DM, Ross CA. Papilloma of the esophagus: association with hiatal hernia. J Thorac Surg 1959;37:625-635
80. Szanto I, Szentirmay Z, Banai J, Nagy P, Gonda G, Voros A. Squamous papilloma of the esophagus. Clinical and pathological observations based on 172 papillomas in 155 patients. Orv Hetil 2005;146:547-552
81. Chang F, Janatuinen E, Pikkarainen P, Syrjänen S, Syrjänen K. Esophageal squamous cell papillomas. Failure to detect human papillomavirus DNA by in situ hybridization and polymerase chain reaction. Scand J Gastroenterol 1991; 26:535-545
82. Lio WJ, Huang CK, Chen GH. Squamous papilloma of the esophagus. Zhonghua Yi Xue Za Zhi (Taipei) 1996; 57:413-417
83. Syrjänen K. HPV infections in other sites and lesions. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 445-458
84. Cheng JY, Sheu LF, Meng CL, Lee WH, Lin JC. Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction. Gut 1995;37:87-90.
85. Cheng JY, Sheu LF, Lin JC, Meng CL. Detection of human papillomavirus DNA in colorectal adenomas. Arch Surg 1995;130:73-76
86. Kirgan D, Manalo P, Hall M, McGregor B. Association of human papillomavirus and colon neoplasms. Arch Surg 1990;125:862-865
87. Kirgan D, Manalo P, McGregor B. Immunohistochemical demonstration of human papilloma virus antigen in human colon neoplasms. J Surg Res 1990;48:397-402.
88. Giuliani L, Ronci C, Bonifacio D, Di Banito L, Favalli C, Perno CF, et al. Detection of oncogenic DNA viruses in colorectal cancer. Anticancer Res 2008;28:1405-1410
89. Damin DC, Caetano MB, Rosito MA, Schwartsmann G, Damin AS, Frazzon AP, et al. Evidence for an association of human papillomavirus infection and colorectal cancer. Eur J Surg Oncol 2007;33:569-574
90. Bodaghi S, Yamanegi K, Xiao SY, Da Costa M, Palefsky JM, Zheng ZM. Colorectal papillomavirus infection in patients with colorectal cancer. Clin Cancer Res 2005;11:2862-2867
91. Perez LO, Abba MC, Laguens RM, Golijow CD. Analysis of adenocarcinoma of the colon and rectum: detection of human papillomavirus (HPV) DNA by polymerase chain reaction. Colorectal Dis 2005;7:492-495
92. Syrjänen K. HPV infections of the anus. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 295-314.
93. Fenger C. The anal transitional zone. Acta Pathol Microbiol Immunol Scand Suppl 1987;289:1-42.
94. Fenger C. Histology of the anal canal. Am J Surg Pathol 1988;12:41-55.
95. Palefsky J. Human papillomavirus associated malignancies in HIV positive men and women. Curr Opin Oncol 1995;7:437-441
96. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Hogeboom CJ, Darragh TM. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med 1997;73:174-180
97. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV) positive and HIV negative homosexual men. J Infect Dis 1998; 177:361-367
98. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high grade squamous intra epithelial lesions among HIV positive and HIV negative homosexual and bisexual men. AIDS 1998;12:495-503.
99. Chang F, Kosunen O, Kosma VM, Syrjänen S, Lahtinen J, Syrjänen K. Verrucous carcinoma of the anus containing human papillomavirus type 16 DNA detected by in situ hybridisation: a case report. Genitourin Med 1990;66:342-345
100. Bertram P, Treutner KH, Rubben A, Hauptmann S, Schumpelick V. Invasive squamous cell carcinoma in giant anorectal condyloma (Buschke-Lowenstein tumor). Langenbecks Arch Chir 1995;380:115-118
101. Fenger C, Nielsen VT. Intraepithelial neoplasia in the anal canal. The appearance and relation to genital neoplasia. Acta Pathol Microbiol Immunol Scand A 1986;94:343-349
102. Scholefield JH, Hickson WG, Smith JH, Rogers K, Sharp F. Anal intraepithelial neoplasia: part of a multifocal disease process. Lancet 1992;340:1271-1273
103. Syrjänen K. HPV infections of the skin. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 315-340
104. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus induced genetic cancer of the skin. Arch Dermatol 1995;131:1312-1318
105. Majewski S, Jablonska S, Orth G. Epidermodysplasia verruciformis as a model for HPV-related oncogenesis. In: Gross G, von Krogh G, editors Human papillomavirus infections in dermatovenereology. Boca Raton: CRC Press; 1997. pp. 131-150
106. Lu S, Syrjänen K, Havu VK, Syrjänen. No evidence of human papillomavirus DNA in actinic keratosis. Arch Dermatol Res 1995;287:649-651
107. Lu S, Syrjänen K, Havu VK, Syrjänen S. Failure to demonstrate human papillomavirus (HPV) involvement in Bowen's disease of the skin. Arch Dermatol Res 1996;289:40-45
108. Tieben LM, Berkhout RJ, Smits HL, Bouwes Bavinck JN, Vermeer BJ, Bruijn JA, et al. Detection of epidermodysplasia verruciformis like human papillomavirus types in malignant and premalignant skin lesions of renal transplant recipients. Br J Dermatol 1994;131:226-230
109. de Jong Tieben LM, Berkhout RJ, Smits HL, Bouwes Bavinck JN, Vermeer BJ, Van der Woude FJ, et al. High frequency of detection of epidermodysplasia verruciformis associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol 1995;105:367-371
110. Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, Messina JL, et al. Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer 2008;123:237-242
111. Marino-Enriquez A, Gonzalez-Rocha T, Burgos E, Stolnicu S, Mendiola M, Nogales FF, et al. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation: a clinicopathologic study of 5 cases and review of the literature. Hum Pathol 2008;39:1606-1613
112. Giatromanolaki A, Sivridis E, Papazoglou D, Koukourakis MI, Maltezos E. Human papillomavirus in endometrial adenocarcinomas: infectious agent or a mere 'passenger'? Infect Dis Obstet Gynecol 2007;2007:60549.
113. Czerwenka K, Lu YX, Heuss F, Manavi M, Kubista E. Human papillomavirus detection of endometrioid carcinoma with squamous differentiation of the uterine corpus. Gynecol Oncol 1996;61:210-214
114. Sherwood JB, Carlson JA, Gold MA, Chou TY, Isacson C, Talerman A. Squamous metaplasia of the endometrium associated with HPV 6 and 11. Gynecol Oncol 1997;66:141-145
115. http://www.stakes.fi/FI/tilastot wesite of Stakes. Visited date: August 24, 2009.
116. Syrjänen S, Shabalova IP, Petrovichev N, Kozachenko VP, Zakharova T, Pajanidi A, et al. Human papillomavirus testing and conventional Pap smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former Soviet Union. J Lower Genital Tract Dis 2002;6:97-110.
117. Syrjänen K, Naud P, Derchain SM, Roteli-Martins C, Longatto-Filho A, Tatti S, et al. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS Study. Anticancer Res 2005;25:3469-3480
118. Sarian L, Derchain SM, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI) cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) Study. J Med Screen 2005;12:142-149
119. Syrjänen K, Hakama M, Saarikoski S, Väyrynen M, Yliskoski M, Syrjänen S, et al. Prevalence, incidence and estimated life-time risk of cervical human papillomavirus (HPV) infections in non-selected Finnish female population. Sex Transm Dis 1990;17:15-19
120. Syrjänen S, Shabalova IP, Petrovichev N, Kozachenko VP, Zakharova T, Pajanidi A, et al. Acquisition of incident highrisk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NIS) of the former Soviet Union. J Clin Microbiol 2004;42:505-511
121. Syrjänen S, Shabalova IP, Petrovichev N, Kozachenko VP, Zakharova T, Pajanidi A, et al. Age-specific incidence and clearance rates of high-risk human papillomavirus (HPV) infections in women subjected to HPV screening in the new independent states. Int J STD AIDS 2005;16:217-233
122. Syrjänen K, Yliskoski M, Kataja V, Hippeläinen M, Syrjänen S, Saarikoski S, et al. Prevalence of genital human papillomavirus (HPV) infections in a mass-screened Finnish female population aged 20-65 years. Int J STD AIDS 1990;1:410-415
123. Syrjänen, K. HPV infections of the vulva. In: Syrjänen K, Syrjänen S. Papillomavirus infections in human pathology. NewYork: J. Wiley & Sons; 2000. pp. 207-232
124. Syrjänen K. HPV infections of the vagina. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 233-248
125. Goodman A. Primary vaginal cancer. Surg Oncol Clin N Am 1998;7:347-361
126. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-1622
127. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-270
128. Ciszko B, Gabrys MS, Pochwalowski M. Can vulvar carcinoma be a danger in the 21st century? Pol Merkuriusz Lek 2005;18:336-338
129. Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG. New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 2008;109:340-345
130. Skapa P, Zamecnik J, Hamsikova E, Salakova M, Smahelova J, Jandova K, et al. Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol 2007;31:1834-1843.
131. Joura EA. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000;45:613-615
132. Akerman G, Dussour C, Haddad B, Paniel BJ, Rouzier R. Epidemiology of vulvar intra-epithelial neoplasias. Gynecol Obstet Fertil 2007;35:1251-1256
133. Anastasiadis P, Skaphida P, Koutlaki N, Boli A, Galazios G, Liberis V. Trends in epidemiology of preinvasive and invasive vulvar neoplasias. 13 year retrospective analysis in Thrace, Greece. Arch Gynecol Obstet 2000;264:74-79
134. Sexually transmitted disease quarterly report: genital warts and herpes simplex virus infections in the UK. CDR Weekly 2003;13:6-9.
135. Syrjänen K. HPV infections in the urinary tract. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 277-294
136. Olson C, Pamukcu AM, Brobst DF. Papilloma-like virus from bovine urinary bladder tumors. Cancer Res 1965; 25:840-852
137. Campo MS, Jarrett WF, Barron R, O'Neil BW, Smith KT. Association of bovine papillomavirus type 2 and bracken fern with bladder cancer in cattle. Cancer Res 1992;52: 6898-6904
138. De Gaetani C, Ferrari G, Righi E, Bettelli S, Migaldi M, Ferrari P, et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation. J Clin Pathol 1999;52:103-106
139. Sur M, Cooper K, Allard U. Investigation of human papillomavirus in transitional cell carcinomas of the urinary bladder in South Africa. Pathology 2001;33:17-20.
140. Ng WK, Cheung LK, Li AS, Cheung FM, Chow JC. Transitional cell metaplasia of the uterine cervix is related to human papillomavirus: molecular analysis in seven patients with cytohistologic correlation. Cancer 2002;96:250-258
141. Wiwanitkit V. Urinary bladder carcinoma and human papilloma virus infection, an appraisal of risk. Asian Pac J Cancer Prev 2005;6:217-218
142. Chang F, Lipponen P, Tervahauta A, Syrjänen S, Syrjänen K. Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction. J Urol 1994;152:1429-1433
143. Syrjänen K. HPV infections in the male. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 249-276
144. Maiche AG. Epidemiological aspects of cancer of the penis in Finland. Eur J Cancer Prev 1992;1:153-158
145. von Krogh G, Syrjänen S, Syrjänen K. Advantage of human papillomavirus typing in the clinical evaluation of genitoanal warts: experience with the in situ deoxyribonucleic acid hybridization technique applied on paraffin sections. J Am Acad Dermatol 1988;18:495-503.
146. Villa LL, Lopes A. Human papillomavirus. DNA sequences in penile carcinomas in Brazil. Int J Cancer 1986;37:853-855
147. Hippeläinen M, Yliskoski M, Saarikoski S, Syrjänen S, Syrjänen K. Genital human papillomavirus lesions of the male sexual partners: the diagnostic accuracy of peniscopy. Genitourin Med 1991;67:291-296
148. Hippeläinen M, Syrjänen S, Koskela H, Pulkkinen J, Saarikoski S, Syrjänen K. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 1993;20:321-328
149. Hippeläinen MI, Syrjänen S, Hippeläinen MJ, Saarikoski S, Syrjänen K. Diagnosis of genital human papillomavirus (HPV) lesions in the male: correlation of peniscopy, histology and in situ hybridisation. Genitourin Med 1993;69:346-351
150. Hippeläinen M. Genital human papillomavirus (HPV) infection in the male. Diagnosis, prevalence, risk factors and clinical course. MD (PhD) Thesis. Finland: Kuopio University Publications D. Medical Sciences; 1994. pp. 1-96.
151. De Carvalho JJ, Syrjänen KJ, Jacobino M, Rosa NT, Carvalho LZ. Prevalence of genital human papillomavirus (HPV) infections established with different diagnostic techniques among males attending a urological clinic. Scand J Urol Nephrol 2006;40:138-143
152. De Carvalho JJ, De Carvalho JZ, Rosa NT, Carvalho LZ, Syrjänen KJ. Identification of males at increased risk for genital human papillomavirus (HPV) infection among patients referred for urological consultation. Scand J Infect Dis 2007;39:1029-1037
153. Väyrynen M, Romppanen T, Koskela E, Castren O, Syrjänen K. Verrucous squamous cell carcinoma of the female genital tract. Report of three cases and survey of the literature. Int J Gynaecol Obstet 1981;19:351-356
154. Syrjänen KJ, Shabalova IP, Petrovichev N, Kozachenko VP, Zakharova T, Pajanidi A, et al. Epidemiological, clinical and viral determinants of the increased prevalence of high-risk human papillomavirus (HPV) infections in elderly women. Eur J Gynecol Oncol 2008;29:114-122